Clinical Trial

A Boston biotech advances a first-in-class antibody into trials, aiming to halt the cellular engine of fibrosis that drives chronic kidney disease.

Skye Salud's move into primary care testing in Mexico is more than a trial; it's a blueprint for deploying resilient, evidence-based AI in regulated industries.

With a $43M funding boost, Irish innovator CroíValve is expanding trials for its unique 'Adaptive Coaptation' device, aiming to transform treatment for millions.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

For bladder cancer patients facing bladder removal, a novel therapy from Sweden offers new hope. A US trial expansion targets the most resistant cases.

SeaStar Medical prepares to present its life-saving organ failure technology to investors. We explore its newly approved product, pivotal adult trial, and vast market potential.

A new patent for 3D fibroblast spheroids could revolutionize chronic wound treatment, giving FibroBiologics a key edge in the burgeoning biotech market.

With compelling Phase 2b survival data, NeuroSense is advancing its multi-target ALS drug to a pivotal Phase 3 trial. A deep dive into the science and strategy.

Prolium Bioscience advances its T-cell engager, PRO-203, in trials for scleroderma and lupus, heralding a new, potent strategy against severe autoimmunity.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.

A new enzyme blend for dogs boasts a 92% success rate in a clinical trial. We analyze the data and what it means for the pet supplement industry's future.

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

Beyond amyloid plaques, a new therapy tackles Alzheimer's by reducing inflammation. Longeveron's latest data offers a glimpse into a regenerative future.

New real-time imaging gives surgeons a 3D molecular map of cancer in the OR, poised to end the emotional and physical toll of reoperations for many.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

BioCardia bets its future on Japan's fast-track approval for its heart therapy, a strategic pivot that could unlock global markets or break the bank.